Key result
Review identifies thrombosis, inflammation, intimal hyperplasia, and atherosclerosis as primary drivers of SVG failure.
Why the study?
The saphenous vein remains the most frequently used conduit for CABG despite unsatisfactory long-term patency rates, motivating a review of vein graft failure pathophysiology and potential new intervention strategies.
What are the pathophysiological mechanisms, prevention strategies, and treatments for saphenous vein graft failure?
What are the pathophysiological mechanisms, prevention strategies, and treatments for saphenous vein graft failure?
This review summarizes the pathophysiology of saphenous vein graft failure and highlights that while surgical and pharmacological interventions improve early patency, long-term patency remains a challenge requiring further research.
Answers are grounded in this paper and cite their sources.
Surgical and pharmacological strategies improve early SVG patency; leaves open durable long-term prevention.
BACKGROUND: The saphenous vein remains the most frequently used conduit for coronary artery bypass grafting, despite reported unsatisfactory long-term patency rates. Understanding the pathophysiology of vein graft failure and attempting to improve its longevity has been a significant area of research for more than three decades. This article aims to review the current understanding of the pathophysiology and potential new intervention strategies. METHODS: A search of three databases: MEDLINE, Web of Science, and Cochrane Library, was undertaken for the terms "pathophysiology," "prevention," and "treatment" plus the term "vein graft failure." RESULTS: Saphenous graft failure is commonly the consequence of four different pathophysiological mechanisms, early acute thrombosis, vascular inflammation, intimal hyperplasia, and late accelerated atherosclerosis. Different methods have been proposed to inhibit or attenuate these pathological processes including modified surgical technique, topical pretreatment, external graft support, and postoperative pharmacological interventions. Once graft failure occurs, the available treatments are either surgical reintervention, angioplasty, or conservative medical management reserved for patients not eligible for either procedure. CONCLUSION: Despite the extensive amount of research performed, the pathophysiology of saphenous vein graft is still not completely understood. Surgical and pharmacological interventions have improved early patency and different strategies for prevention seem to offer some hope in improving long-term patency.
No takes yet. Share an insight, caveat, or question.
Guida et al. (2020) conducted a review in Saphenous vein graft disease. A review of the literature indicates that saphenous vein graft failure is driven by thrombosis, inflammation, intimal hyperplasia, and atherosclerosis, with various strategies proposed for prevention.
Synapse has enriched 10 related papers. Consider them for comparative context: